Page 163 - Read Online

Page 10 of 10 Sullivan et al. Hepatoma Res 2018;4:68 I http://dx.doi.org/10.20517/2394-5079.2018.95

hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.
49. Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, et al. Treatment variables related to liver toxicity in patients with
hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol
2015;5:e443-e9.
50. Weiner AA, Olsen J, Ma D, Dyk P, DeWees T, et al. Stereotactic body radiotherapy for primary hepatic malignancies - report of a phase I/II
institutional study. Radiother Oncol 2016;121:79-85.
51. Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial
chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 2016;122:2041-9.
52. Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic
body radiotherapy for hepatocellular carcinoma. Oncotarget 2016;7:40756-66.
53. Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, et al. A prospective study of hypofractionated proton beam therapy for
patients with hepatocellular carcinoma. Int J Radiat Oncol 2009;74:831-6.
54. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, et al. Phase II study of radiotherapy employing proton beam for hepatocellular
carcinoma. J Clin Oncol 2005;23:1839-46.
55. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a
phase 2 prospective trial. Cancer 2011;117:3053-9.
56. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam
therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.
57. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, et al. A prospective randomized trial comparing percutaneous local ablative therapy and
partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8.
58. Huang J, Yan L, Cheng Z, Wu H, Du L, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC
conforming to the Milan criteria. Ann Surg 2010;252:903-12.
59. Feng K, Yan J, Li X, Xia F, Ma K, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of
small hepatocellular carcinoma. J Hepatol 2012;57:794-802.
60. Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, et al. Randomized clinical trial of hepatic resection versus radiofrequency
ablation for early-stage hepatocellular carcinoma. Br J Surg 2017;104:1775-84.
61. Yin L, Li H, Li AJ, Lau WY, Pan ZY, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple
hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol 2014;61:82-8.
62. Yuan BH, Yuan WP, Li RH, Xiang BD, Gong WF, et al. Propensity score-based comparison of hepatic resection and transarterial
chemoembolization for patients with advanced hepatocellular carcinoma. Tumour Biol 2016;37:2435-41.
63. Liu PH, Hsia CY, Lee YH, Hsu CY, Huang YH, et al. Surgical resection versus transarterial chemoembolization for BCLC stage C
hepatocellular carcinoma. J Surg Oncol 2015;111:404-9.
64. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, et al. Hepatic resection associated with good survival for selected patients with intermediate
and advanced-stage hepatocellular carcinoma. Ann Surg 2014;260:329-40.
65. Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, et al. Role of hepatic resection in patients with intermediate-stage hepatocellular
carcinoma: a multicenter study from Japan. Cancer Sci 2017;108:1414-20.
66. Hyun MH, Lee YS, Kim JH, Lee CU, Jung YK, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage
hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology 2018; doi: 10.1002/hep.29883.
67. Liu PH, Lee YH, Hsu CY, Huang YH, Chiou YY, et al. Survival advantage of radiofrequency ablation over transarterial chemoembolization
for patients with hepatocellular carcinoma and good performance status within the Milan criteria. Ann Surg Oncol 2014;21:3835-43.
68. Chen RX, Gan YH, Ge NL, Chen Y, Ma H, et al. Comparison of transarterial chemoembolization with radiofrequency ablation for
unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. J Gastroenterol Hepatol
2016;31:442-9.
69. Ishikawa K, Chiba T, Ooka Y, Suzuki E, Ogasawara S, et al. Transarterial chemoembolization as a substitute to radiofrequency ablation for
treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget 2018;9:21560-8.
70. Berger NG, Tanious MN, Hammad AY, Miura JT, Mogal H, et al. External radiation or ablation for solitary hepatocellular carcinoma: a
survival analysis of the SEER database. J Surg Oncol 2017;116:307-12.
71. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for
hepatocellular carcinoma. J Clin Oncol 2016;34:452-9.
72. Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, et al. Randomized clinical trial comparing proton beam radiation therapy with
transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys 2016;95:477-82.
73. Gilligan AM, Alberts DS, Roe DJ, Skrepnek GH. Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-
Diagnosed Cancer. Am J Med 2018; doi: 10.1016/j.amjmed.2018.05.020.
74. Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, et al. Cost-effectiveness of stereotactic body radiation therapy versus
radiofrequency ablation for hepatocellular carcinoma: a markov modeling study. Radiology 2017;283:460-8.
75. Thein H-H, Qiao Y, Zaheen A, Jembere N, Sapisochin G, et al. Cost-effectiveness analysis of treatment with non-curative or palliative intent
for hepatocellular carcinoma in the real-world setting. PLOS ONE 2017;12:e0185198.
76. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy
vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol 2018;4:661-9.
77. Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, et al. Stereotactic body radiation therapy combined with transcatheter arterial
chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:530-6.
78. Fang Y, Chen W, Liang X, Li D, Lou H, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with
hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:193-200.